Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenome.
A comprehensive genetic analysis of dedifferentiated liposarcomas suggests that epigenetic modifications are common and may alter the differentiation capacity in these tumors. Furthermore, these data suggest that treatment strategies aimed at altering histone acetylation and/or DNA methylation are worthy of further study.